Best practices : appropriate use of the new β-lactam/ β-lactamase inhibitor combinations, ceftazidimeavibactam and ceftolozane-tazobactam in South Africa
JavaScript is disabled for your browser. Some features of this site may not work without it.
Please be advised that the site will be down for maintenance on Sunday, September 1, 2024, from 08:00 to 18:00, and again on Monday, September 2, 2024, from 08:00 to 09:00. We apologize for any inconvenience this may cause.
Best practices : appropriate use of the new β-lactam/ β-lactamase inhibitor combinations, ceftazidimeavibactam and ceftolozane-tazobactam in South Africa
Antibiotic stewardship of hospital-acquired infections because of difficult-to-treat resistant
(DTR) Gram-negative bacteria is a global challenge. Their increasing prevalence in South
Africa has required a shift in prescribing in recent years towards colistin, an antibiotic of
last resort. High toxicity levels and developing resistance to colistin are narrowing treatment
options further. Recently, two new β-lactam/β-lactamase inhibitor combinations,
ceftazidime-avibactam and ceftolozane-tazobactam were registered in South Africa,
bringing hope of new options for management of these life-threatening infections. However,
with increased use in the private sector, increasing levels of resistance to ceftazidimeavibactam
are already being witnessed, putting their long-term viability as treatment
options of last resort, in jeopardy. This review focuses on how these two vital new antibiotics
should be stewarded within a framework that recognises the resistance mechanisms
currently predominant in South Africa’s multi-drug and DTR Gram-negative bacteria.
Moreover, the withholding of their use for resistant infections that can be treated with
currently available antibiotics is a critical part of stewardship, if these antibiotics are to be
conserved in the long term.